Publications

The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Please access the link: https://www.sciencedirect.com/science/article/abs/pii/S014521261300194X#

Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Please access the link: https://www.nature.com/articles/bcj201662

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.
Please access the link: https://www.sciencedirect.com/science/article/pii/S1658387618300335

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Please access the link: https://pubmed.ncbi.nlm.nih.gov/31171473/

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Please access the link: https://pubmed.ncbi.nlm.nih.gov/32630644/

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
Please access the link: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/34480015/

Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
Please access the link: https://www.nature.com/articles/bmt201643